For example, carotuximab, a humanized monoclonal antibody that can potentially inhibit CD105-mediated signaling, has shown limited clinical benefit as an anti-angiogenic agent in prostate cancer patients [45]. This evidence concerns the gene ENG and Familial prostate cancer.